Name: INF39
Price: 268.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    INF39 is a nontoxic, irreversible inhibitor of the nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain containing protein 3 (NLRP3). NLRP3 is an intracellular sensor that detects a variety of endogenous danger signals, microbial motifs as well as environmental irritants, resulting in the formation and activation of the NLRP3 inflammasome. Assembly of the NLRP3 inflammasome leads to caspase 1-dependent release of pro-inflammatory cytokines (e.g. IL-1β and IL-18), as well as to gasdermin D-induced pyroptotic cell death. Pharmacological inhibition of NLRP3 inflammasome activation has been shown to offer a new option in the treatment of inflammatory bowel disease.
    
    1. Cocco M, Pellegrini C, Martínez-Banaclocha H, et al. Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease. Journal of Medicinal Chemistry, 2017, 60(9): 3656-3671.
    2. Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nature Reviews Immunology, 2019, 19(8): 477-489.
- Properties
  - Alternative Name
    
    ethyl 2-(2-chlorobenzyl)acrylate
    
    CAS Number
    
    866028-26-4
    
    Molecular Formula
    
    C12H13ClO2
    
    Molecular Weight
    
    224.68
    
    Purity
    
    98.00%
    
    Solubility
    
    ≥22.5 mg/mL in DMSO; ≥41.9 mg/mL in H2O; ≥47.9 mg/mL in EtOH
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

INF39

INF39

Background

We Also Recommend

AS1842856

DiZPK

PKM2 inhibitor(compound 3k)